{
    "status": "ok",
    "totalResults": 18,
    "articles": [
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call",
            "description": "(marketscreener.com) \nPulse Biosciences will host a conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023\n\nhttps://www.marketscreener.com/quote/stock/PULSE-BIOSCIENCES-INC-27723990/news/UPDATE-Pulse-Biosciences-Announces-New-Time-for-Third-\u2026",
            "url": "https://www.marketscreener.com/quote/stock/PULSE-BIOSCIENCES-INC-27723990/news/UPDATE-Pulse-Biosciences-Announces-New-Time-for-Third-Quarter-2023-Financial-Results-Conference-Call-45302753/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-10T21:57:02Z",
            "content": "Pulse Biosciences will host a conference call at 9:00 am PT / 12:00 pm ET on Monday, November 13, 2023\r\nPulse Biosciences, Inc. (Nasdaq: PLSE, the Company), a company primarily focused on leveraging \u2026 [+1585 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Pulse Biosciences (NASDAQ:PLSE) Shares Gap Up to $8.84",
            "description": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report)\u2019s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $8.84, but opened at $9.04. Pulse Biosciences shares last traded at $9.27, with a volume of 127,320 shares traded.\u2026",
            "url": "https://www.etfdailynews.com/2023/11/30/pulse-biosciences-nasdaqplse-shares-gap-up-to-8-84/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-11-30T13:34:47Z",
            "content": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report)\u2019s stock price gapped up prior to trading on Tuesday . The stock had previously closed at $8.84, but opened at $9.04. Pulse Biosciences shares l\u2026 [+3769 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode",
            "description": "(marketscreener.com) \nPulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today announced the filing of a premarket notifica\u2026",
            "url": "https://www.marketscreener.com/quote/stock/PULSE-BIOSCIENCES-INC-27723990/news/Pulse-Biosciences-Files-510-k-Submission-with-U-S-FDA-for-its-CellFX-nsPFA-Percutaneous-Electrode-45407796/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-21T13:04:02Z",
            "content": "Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibr\u2026 [+4805 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference",
            "description": "(marketscreener.com) \nPulse Biosciences, Inc. , a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 3\u2026",
            "url": "https://www.marketscreener.com/quote/stock/PULSE-BIOSCIENCES-INC-27723990/news/Pulse-Biosciences-to-Present-at-the-35th-Annual-Piper-Sandler-Healthcare-Conference-45365026/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-15T21:09:02Z",
            "content": "Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibr\u2026 [+1341 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Pulse Biosciences Up 16% on Product Updates, Potential Stock Purchases by Duggan",
            "description": "(marketscreener.com) \n By Josh Beckerman \n\n Pulse Biosciences shares rose 16% after the bioelectric medicine company issued product updates and said controlling stockholder and Chairman Robert W. Duggan is evaluating potential purchases of company stock. \n\n T\u2026",
            "url": "https://www.marketscreener.com/quote/stock/PULSE-BIOSCIENCES-INC-27723990/news/Pulse-Biosciences-Up-16-on-Product-Updates-Potential-Stock-Purchases-by-Duggan-45444840/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-27T20:37:02Z",
            "content": "By Josh Beckerman \r\nPulse Biosciences shares rose 16% after the bioelectric medicine company issued product updates and said controlling stockholder and Chairman Robert W. Duggan is evaluating potent\u2026 [+625 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Pulse Biosciences (NASDAQ:PLSE) Sees Strong Trading Volume",
            "description": "Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) saw unusually-high trading volume on Monday . Approximately 273,593 shares traded hands during mid-day trading, an increase of 92% from the previous session\u2019s volume of 142,772 shares.The stock\u2026",
            "url": "https://www.etfdailynews.com/2023/12/04/pulse-biosciences-nasdaqplse-sees-strong-trading-volume/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-12-04T17:58:46Z",
            "content": "Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) saw unusually-high trading volume on Monday . Approximately 273,593 shares traded hands during mid-day trading, an increase of 92% fr\u2026 [+4181 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Pulse Biosciences Shares Climb On Application for Percutaneous Electrode Review",
            "description": "(marketscreener.com) \n By Sabela Ojea \n\n\n Shares of Pulse Biosciences jumped on Tuesday after the company said that it submitted a Food and Drug Administration premarket application for its CellFX nsPFA percutaneous electrode. \n\n Shares were recently up 15% a\u2026",
            "url": "https://www.marketscreener.com/quote/stock/PULSE-BIOSCIENCES-INC-27723990/news/Pulse-Biosciences-Shares-Climb-On-Application-for-Percutaneous-Electrode-Review-45410067/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdnoir.png",
            "publishedAt": "2023-11-21T17:15:03Z",
            "content": "By Sabela Ojea \r\nShares of Pulse Biosciences jumped on Tuesday after the company said that it submitted a Food and Drug Administration premarket application for its CellFX nsPFA percutaneous electrod\u2026 [+909 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Pulse Biosciences (NASDAQ:PLSE) Upgraded at StockNews.com",
            "description": "Pulse Biosciences (NASDAQ:PLSE \u2013 Get Free Report) was upgraded by investment analysts at StockNews.com to a \u201csell\u201d rating in a research note issued on Monday. Pulse Biosciences Price Performance Shares of NASDAQ PLSE traded up $0.14 during midday trading on M\u2026",
            "url": "https://www.etfdailynews.com/2023/11/21/pulse-biosciences-nasdaqplse-upgraded-at-stocknews-com/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T05:10:41Z",
            "content": "Pulse Biosciences (NASDAQ:PLSE \u2013 Get Free Report) was upgraded by investment analysts at StockNews.com to a \u201csell\u201d rating in a research note issued on Monday.\r\nPulse Biosciences Price Performance\r\nSh\u2026 [+4153 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Pulse Biosciences, Inc. (NASDAQ:PLSE) Insider Mitchell E. Levinson Buys 4,261 Shares",
            "description": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) insider Mitchell E. Levinson purchased 4,261 shares of the stock in a transaction on Wednesday, November 15th. The shares were bought at an average price of $5.87 per share, for a total transaction of $2\u2026",
            "url": "https://www.etfdailynews.com/2023/11/18/pulse-biosciences-inc-nasdaqplse-insider-mitchell-e-levinson-buys-4261-shares/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-11-18T14:58:42Z",
            "content": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) insider Mitchell E. Levinson purchased 4,261 shares of the stock in a transaction on Wednesday, November 15th. The shares were bought at an ave\u2026 [+2623 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Robert W. Duggan Acquires 124,397 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) Stock",
            "description": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) Director Robert W. Duggan bought 124,397 shares of the stock in a transaction on Tuesday, November 28th. The shares were purchased at an average price of $8.98 per share, with a total value of $1,117,085\u2026",
            "url": "https://www.etfdailynews.com/2023/12/01/robert-w-duggan-acquires-124397-shares-of-pulse-biosciences-inc-nasdaqplse-stock/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-12-01T14:20:42Z",
            "content": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) Director Robert W. Duggan bought 124,397 shares of the stock in a transaction on Tuesday, November 28th. The shares were purchased at an averag\u2026 [+2625 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Pulse Biosciences (PLSE) Scheduled to Post Quarterly Earnings on Monday",
            "description": "Pulse Biosciences (NASDAQ:PLSE \u2013 Get Free Report) is scheduled to be announcing its earnings results after the market closes on Monday, November 13th. Individual that are interested in participating in the company\u2019s earnings conference call can do so using th\u2026",
            "url": "https://www.etfdailynews.com/2023/11/06/pulse-biosciences-plse-scheduled-to-post-quarterly-earnings-on-monday/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-11-06T12:41:25Z",
            "content": "Pulse Biosciences (NASDAQ:PLSE \u2013 Get Free Report) is scheduled to be announcing its earnings results after the market closes on Monday, November 13th. Individual that are interested in participating \u2026 [+2706 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Pulse Biosciences (NASDAQ:PLSE) Shares Up 4.9% Following Insider Buying Activity",
            "description": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report)\u2019s stock price shot up 4.9% on Friday after an insider bought additional shares in the company. The stock traded as high as $9.55 and last traded at $9.47. 31,435 shares were traded during trading, a decl\u2026",
            "url": "https://www.etfdailynews.com/2023/12/01/pulse-biosciences-nasdaqplse-shares-up-4-9-following-insider-buying-activity/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-12-01T15:32:41Z",
            "content": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report)\u2019s stock price shot up 4.9% on Friday after an insider bought additional shares in the company. The stock traded as high as $9.55 and last trade\u2026 [+4008 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "ETF Daily News"
            },
            "author": "MarketBeat News",
            "title": "Robert W. Duggan Buys 20,241 Shares of Pulse Biosciences, Inc. (NASDAQ:PLSE) Stock",
            "description": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) Director Robert W. Duggan acquired 20,241 shares of the company\u2019s stock in a transaction on Friday, November 17th. The stock was acquired at an average price of $6.10 per share, with a total value of $12\u2026",
            "url": "https://www.etfdailynews.com/2023/11/20/robert-w-duggan-buys-20241-shares-of-pulse-biosciences-inc-nasdaqplse-stock/",
            "urlToImage": "https://www.americanbankingnews.com/wp-content/timthumb/timthumb.php?src=https://www.marketbeat.com/logos/pulse-biosciences-inc-logo.png?v=20221223071004&w=240&h=240&zc=2",
            "publishedAt": "2023-11-21T02:26:49Z",
            "content": "Pulse Biosciences, Inc. (NASDAQ:PLSE \u2013 Get Free Report) Director Robert W. Duggan acquired 20,241 shares of the company\u2019s stock in a transaction on Friday, November 17th. The stock was acquired at an\u2026 [+2873 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "MarketWatch"
            },
            "author": "Tomi Kilgore",
            "title": ": Ventyx Biosciences\u2019 stock suffering record plunge after psoriasis treatment trial fails to meet internal efficacy target",
            "description": "Shares of Ventyx Biosciences Inc. VTYX plunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaque psoriasis and psoriatic arthritis treatments. The stock, which was the \u2026",
            "url": "https://www.marketwatch.com/story/ventyx-biosciences-stock-suffering-record-plunge-after-psoriasis-treatment-trial-fails-to-meet-internal-efficacy-target-d2706dd2",
            "urlToImage": "https://s.wsj.net/public/resources/MWimages/MW-GP644_MicroS_ZG_20180906154215.jpg",
            "publishedAt": "2023-11-07T12:15:00Z",
            "content": "Shares of Ventyx Biosciences Inc. \r\n VTYX,\r\n -9.56%\r\nplunged 73.7% in premarket trading Tuesday, after the biopharmaceutical company said it has decided not to support further development of its plaq\u2026 [+832 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "GlobeNewswire"
            },
            "author": "PIONEERING MARKETDIGITS CONSULTING AND ADVISORY PRIVATE LIMITED",
            "title": "Pulsed Field Ablation Market projected to surpass USD USD 6.2 Million by 2030, growing at a CAGR of 23.9% during the forecast period of 2023-2030 - pronounced by MarketDigits in its comprehensive study.",
            "description": "The Global Pulsed Field Ablation Market was valued USD 1.4 Million in 2023 and projected to reach USD USD 6.2 Million by 2030, growing at a CAGR of 23.9% during the forecast period of 2023-2030. The Global Pulsed Field Ablation Market was valued USD 1.4 Milli\u2026",
            "url": "https://www.globenewswire.com/news-release/2023/11/17/2782424/0/en/Pulsed-Field-Ablation-Market-projected-to-surpass-USD-USD-6-2-Million-by-2030-growing-at-a-CAGR-of-23-9-during-the-forecast-period-of-2023-2030-pronounced-by-MarketDigits-in-its-co.html",
            "urlToImage": "https://ml.globenewswire.com/Resource/Download/2960b872-d623-4363-9973-e881f17bf42f",
            "publishedAt": "2023-11-17T09:30:00Z",
            "content": "Richmond, Nov. 17, 2023 (GLOBE NEWSWIRE) -- According to a research report \"Pulsed Field Ablation Market\r\n, by Therapeutic Area (Cardiovascular Disorders, Oncological Disorders, Respiratory Disorders\u2026 [+10913 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2023",
            "description": "(marketscreener.com) \nEnrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3\n\n\nContinuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of 2024\n\n\nManmeet S. Soni Joined Summit as COO, Inv\u2026",
            "url": "https://www.marketscreener.com/quote/stock/SUMMIT-THERAPEUTICS-INC-21452860/news/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nin-45259316/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-07T12:10:02Z",
            "content": "Enrollment Initiated in Second Phase III Clinical Study for Ivonescimab, HARMONi-3\r\nContinuing Enrollment of HARMONi Phase III Study, with Enrollment Completion Expected in Second Half of 2024\r\nManme\u2026 [+23084 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Marketscreener.com"
            },
            "author": null,
            "title": "GE HealthCare Showcases More Than 40 Innovations, Including AI-Enabled Imaging Technology Solutions Designed for Precision Care at RSNA23",
            "description": "(marketscreener.com) \nBooth will highlight new product introductions, key innovations, and AI-enabled advancements from the company\u2019s comprehensive portfolio of Imaging, Ultrasound, and digital solutions designed to optimize patient care and increase operatio\u2026",
            "url": "https://www.marketscreener.com/quote/stock/GE-HEALTHCARE-TECHNOLOGIE-148175835/news/GE-HealthCare-Showcases-More-Than-40-Innovations-Including-AI-Enabled-Imaging-Technology-Solutions-45439017/",
            "urlToImage": "https://www.marketscreener.com/images/twitter_MS_fdblanc.png",
            "publishedAt": "2023-11-26T14:01:02Z",
            "content": "Booth (#7326) will highlight new product introductions, key innovations, and AI-enabled advancements from the companys comprehensive portfolio of Imaging, Ultrasound, and digital solutions designed t\u2026 [+14432 chars]"
        },
        {
            "source": {
                "id": null,
                "name": "Plos.org"
            },
            "author": "Ahmad H. Alhowail, Matthew Eggert, Jenna Bloemer, Priyanka D. Pinky, Lauren Woodie, Subhrajit Bhattacharya, Dwipayan Bhattacharya, Manal A. Buabeid, Bruce Smith, Muralikrishnan Dhanasekaran, Gary Piazza, Miranda N. Reed, Martha Escobar, Robert D. Arnold, Vishnu Suppiramaniam",
            "title": "Phenyl-2-aminoethyl selenide ameliorates hippocampal long-term potentiation and cognitive deficits following doxorubicin treatment",
            "description": "Chemotherapy-induced memory loss (\u201cchemobrain\u201d) can occur following treatment with the widely used chemotherapeutic agent doxorubicin (DOX). However, the mechanisms through which DOX induces cognitive dysfunction are not clear, and there are no commercially a\u2026",
            "url": "https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0294280",
            "urlToImage": "https://journals.plos.org/plosone/article/figure/image?id=10.1371/journal.pone.0294280.g003&size=inline",
            "publishedAt": "2023-11-10T14:00:00Z",
            "content": "Abstract\r\nChemotherapy-induced memory loss (chemobrain) can occur following treatment with the widely used chemotherapeutic agent doxorubicin (DOX). However, the mechanisms through which DOX induces \u2026 [+39016 chars]"
        }
    ]
}